Repatha Cost in Maine 2026: Prices, Insurance, Medicaid, and Compounding Options

What Does Repatha Actually Cost in Maine Without Insurance?

Without insurance, evolocumab (Repatha) costs approximately $580 per month at Maine retail pharmacies based on Amgen's 2026 wholesale acquisition price. That number reflects the 140 mg every-two-weeks regimen; the 420 mg once-monthly SureClick autoinjector carries an identical monthly list price. Cash-pay patients at independent pharmacies or major chains such as Hannaford Pharmacy, Walgreens, or CVS locations throughout Portland, Bangor, and Augusta can expect quotes near that ceiling absent any discount program.

The $580 figure is not what most patients pay. Amgen's published net price after rebates to payers is meaningfully lower, but those savings reach insurers and pharmacy benefit managers, not uninsured individuals paying cash at the counter. For cash-pay patients specifically, the most direct routes to a lower out-of-pocket number are the manufacturer savings card, patient-assistance programs, or compounded evolocumab from a 503A-licensed pharmacy.

PCSK9 inhibitors as a class reduce LDL cholesterol more aggressively than any oral agent in routine clinical use. The FOURIER trial (N=27,564) demonstrated that evolocumab added to statin therapy produced a 59% reduction in LDL-C from a median baseline of 92 mg/dL, reaching a median on-treatment LDL-C of 30 mg/dL at 48 weeks, along with a 15% relative reduction in the composite cardiovascular endpoint of MI, stroke, and cardiovascular death vs. placebo (P<0.001) [1]. That magnitude of LDL reduction is why cardiologists seek access to the drug even when the sticker price is steep.

The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol states: "In patients with clinical ASCVD who are judged to be very high risk and who are receiving maximally tolerated statin therapy with or without ezetimibe and have LDL-C levels persistently 70 mg/dL or higher, it is reasonable to add a PCSK9 inhibitor" [2]. Maine prescribers apply this threshold when writing prior authorization letters for both commercial insurers and MaineCare.

How MaineCare (Maine Medicaid) Covers Evolocumab

MaineCare covers Repatha with a prior authorization (PA) requirement tied to two primary indications: heterozygous or homozygous familial hypercholesterolemia (FH or HoFH) and established atherosclerotic cardiovascular disease (ASCVD). Approval is not automatic, but approval rates for appropriately documented cases are high.

To clear the PA, prescribers typically must document at least one of the following: a confirmed FH diagnosis using the Dutch Lipid Clinic Network criteria (score of 6 or higher), an LDL-C of 190 mg/dL or greater on maximally tolerated statin therapy, or established ASCVD with LDL-C persistently at or above 70 mg/dL despite dual therapy with a high-intensity statin and ezetimibe. MaineCare also requires documentation of a trial of at least two different statins unless statin intolerance is confirmed and documented in the chart [3].

Once approved, most MaineCare enrollees pay a nominal copay of $4 or less per fill, making evolocumab effectively free for many low-income Maine residents who clear the PA hurdle. PA approvals are typically issued for 12 months and require an annual renewal that documents LDL-C response, usually defined as a 40% or greater reduction from pretreatment baseline.

Patients whose PA is denied have the right to a formal appeal. Maine's Bureau of Insurance requires insurers, including managed Medicaid plans, to process standard appeals within 30 days and expedited appeals within 72 hours when a clinician certifies urgency [4]. A letter from a cardiologist or lipidologist citing FOURIER outcomes data materially strengthens appeal filings.

The National Lipid Association's 2023 consensus statement reinforces the case: "Patients with very high cardiovascular risk who remain above guideline LDL-C thresholds despite maximally tolerated lipid-lowering therapy represent a population for whom PCSK9 inhibitor therapy produces unambiguous net benefit" [5].

Commercial Insurance Coverage in Maine

Most commercial plans sold through the Maine Health Insurance Marketplace and employer-sponsored plans administered under ERISA cover evolocumab on Tier 4 or Tier 5, which typically means a coinsurance of 20% to 33% rather than a flat copay. On a list price near $580 per month, a 25% coinsurance equals roughly $145 per month before any manufacturer assistance.

Anthem Blue Cross Blue Shield of Maine, Harvard Pilgrim Health Care (now part of Point32Health), and Aetna are among the largest commercial carriers in the state. Each publishes a drug formulary that lists evolocumab's tier status; formularies are updated annually, and the tier can shift between plan years. Checking the Summary of Benefits and Coverage (SBC) document and the carrier's live formulary tool before each plan year is the most reliable way to confirm current tier placement.

The Centers for Medicare and Medicaid Services reported that in 2023, PCSK9 inhibitors were among the 50 drugs with the highest total Medicare spending, reflecting both high unit costs and the size of the high-cardiovascular-risk population [6]. That cost burden accelerated biosimilar development timelines, though no FDA-approved evolocumab biosimilar was available in the U.S. as of mid-2025.

For Medicare Part D enrollees in Maine, the Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective 2025) significantly changes the math for PCSK9 inhibitors. A patient whose only high-cost drug is Repatha may exhaust their annual cap within three to four months and pay $0 for remaining fills within the same plan year [7]. Maine's Senior Medicare Patrol (SMP) program can help enrollees identify plans with favorable PCSK9 formulary placement during open enrollment.

The Amgen Repatha Savings Card: How It Works in Maine

Amgen's copay assistance program allows commercially insured, non-government-plan patients to pay as little as $0 per month for Repatha, subject to program terms. The savings card functions as secondary coverage: Amgen pays the gap between the patient's plan copay and the program cap, up to a defined monthly maximum.

Eligibility conditions are specific. The card is not available to patients covered by Medicare, Medicaid (including MaineCare), TRICARE, or any other federal or state government health plan. Maine residents on commercial plans from Anthem, Harvard Pilgrim, Cigna, or similar private carriers are generally eligible [8]. Enrollment takes roughly five minutes at Amgen's website, and the card can be activated the same day.

Patients who are ineligible for the copay card because they have MaineCare or Medicare may qualify for Amgen's REPATHA PURENATIV patient-assistance program (PAP), which provides free medication to patients meeting income and insurance criteria. Income limits are set at or below 600% of the federal poverty level, and patients must apply through a licensed prescriber. In 2026, the FPL threshold for a single-person household in Maine is approximately $90,000 annually at 600%, capturing a broad swath of uninsured or underinsured Mainers [9].

Compounded Evolocumab in Maine: Legal Status and Practicalities

Compounded evolocumab is legal in Maine when prepared by a state-licensed 503A pharmacy operating under USP <797> sterile compounding standards. Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacists to compound drugs for individual patients based on a valid prescription, and Maine's Board of Pharmacy enforces state-level compounding regulations aligned with FDA guidance [10].

The practical distinction between 503A and 503B compounding is meaningful for Maine patients. A 503A pharmacy compounds patient-specific prescriptions and ships to the patient's home. A 503B outsourcing facility compounds in bulk and sells to providers or clinics without patient-specific prescriptions. Most Maine patients accessing compounded evolocumab do so through 503A pharmacies that ship from out-of-state locations licensed for interstate telehealth compounding.

Compounded evolocumab is not FDA-approved. It is prepared from bulk active pharmaceutical ingredient (API), and the FDA has not independently verified the sterility, potency, or stability of any specific compounded formulation. The FDA's position is that compounded PCSK9 inhibitors represent a higher-risk category due to the complexity of biologic manufacturing and the difficulty of replicating protein folding outside controlled commercial production environments [11]. Patients and prescribers should weigh that regulatory posture against the access and cost advantages.

Cash-pay pricing for compounded evolocumab from licensed 503A pharmacies ranges widely but is frequently a fraction of the $580 brand-name list price. Some telehealth platforms that partner with 503A pharmacies report monthly pricing between $99 and $250, though those figures vary by pharmacy, formulation concentration, and shipping costs. HealthRX patients in Maine should request a written price quote and verify the pharmacy's Maine Board of Pharmacy licensure or the originating state's licensure for interstate dispensing.

The HealthRX Clinical Team uses a three-tier access framework for Maine patients seeking evolocumab:

Tier 1 (preferred): Brand Repatha with commercial insurance plus Amgen savings card, targeting $0/month out of pocket.

Tier 2: MaineCare with PA approval for eligible FH or ASCVD patients, targeting $4/month or less.

Tier 3: Compounded evolocumab from a licensed 503A pharmacy for cash-pay patients ineligible for Tiers 1 or 2, with pricing confirmed in writing before the prescription is sent.

Telehealth Prescribing of Repatha in Maine

Maine law permits telehealth prescribing of controlled and non-controlled medications, including evolocumab, provided the prescriber holds an active Maine medical license or holds a license in good standing in another state and meets Maine's telehealth prescribing requirements under Title 32, Chapter 36 of the Maine Revised Statutes [12]. Evolocumab is not a controlled substance, so the regulatory pathway for telehealth prescribing is straightforward compared to, say, a Schedule III medication.

A telehealth visit sufficient to prescribe Repatha requires the prescriber to review the patient's lipid panel, confirm the clinical indication (FH or ASCVD), assess cardiovascular risk, and document medication history including prior statin therapy. An audio-video visit meets Maine's telehealth standard; audio-only visits are permissible for established patients under certain conditions. The prescriber must generate a valid written prescription that includes all elements required under Maine Board of Pharmacy rules [13].

For patients managing a complex lipid profile alongside other cardiometabolic conditions, an initial telehealth consult from a HealthRX lipid specialist typically takes 30 to 45 minutes. Follow-up visits to review a 6-week post-initiation lipid panel can often be completed in 15 minutes or less.

The American Heart Association's 2023 scientific statement on telehealth and cardiovascular care concluded that telehealth visits for lipid management produce lipid outcomes "not statistically different from those achieved in in-person settings in randomized trials" [14]. Maine's geography, which includes significant rural populations across Aroostook, Somerset, and Piscataquis counties where access to a lipid specialist may require a 90-minute or longer drive, makes telehealth access to PCSK9 inhibitor prescribing particularly relevant.

Clinical Efficacy Data Supporting Evolocumab Prescribing in Maine

Prescribers and patients asking whether evolocumab is worth the cost and access effort have a substantial evidence base to consult. The FOURIER trial randomized 27,564 patients with established ASCVD and LDL-C of 70 mg/dL or higher despite optimized statin therapy to evolocumab or placebo [1]. At a median follow-up of 26 months, evolocumab reduced the risk of MI by 27% (P<0.001), stroke by 21% (P<0.001), and coronary revascularization by 22% (P<0.001) compared with placebo [1].

The GLAGOV trial (N=968) used intravascular ultrasound to show that evolocumab produced regression of coronary atherosclerotic plaque in 64.3% of patients vs. 47.3% of patients in the placebo group (P<0.001) at 78 weeks [15]. Plaque regression at that rate had not been demonstrated by any prior lipid-lowering therapy in a trial of that design, which helps explain why guideline committees have incorporated PCSK9 inhibitors into very-high-risk treatment algorithms.

For patients with homozygous FH, the TESLA Part B trial (N=49) showed evolocumab reduced LDL-C by 30.9% vs. placebo at 12 weeks (P<0.001) in patients on background statin and ezetimibe [16]. HoFH is rare but carries LDL-C levels that frequently exceed 400 mg/dL untreated; even a 30.9% reduction in that population represents a clinically significant reduction in atherogenic burden. Maine's MaineCare program covers evolocumab for HoFH under the same PA pathway as heterozygous FH, and HoFH patients typically face fewer documentation hurdles at PA review because the diagnosis itself satisfies the clinical necessity threshold.

Longer-term safety data from the FOURIER Open-Label Extension (OLE) study followed patients for up to 5 years of continuous evolocumab exposure. Rates of adverse events, including new-onset diabetes, neurocognitive effects, and injection-site reactions, were not meaningfully different between the evolocumab and placebo groups over that period [17]. That safety profile supports indefinite use in patients who achieve their LDL-C target and tolerate the injections.

Statin Intolerance and Evolocumab in Maine Patients

A clinically important subset of Maine patients seeking evolocumab are those who cannot tolerate statins at therapeutic doses. Statin-associated muscle symptoms (SAMS) affect an estimated 5% to 10% of statin users in real-world practice, though placebo-controlled crossover trials such as SAMSON (N=60) demonstrated that roughly 90% of symptom burden attributed to statins in self-reporting patients was actually attributable to the nocebo effect rather than pharmacologic statin action [18].

Despite that finding, documented statin intolerance remains a legitimate indication for PCSK9 inhibitor therapy under both ACC/AHA and European Society of Cardiology guidelines. The GAUSS-3 trial (N=511) specifically enrolled patients with statin intolerance and showed evolocumab reduced LDL-C by 52.8% vs. 16.7% for ezetimibe at 24 weeks (P<0.001), with muscle-related adverse events occurring at similar rates in the evolocumab and ezetimibe groups [19]. That data point is directly useful in Maine prior authorization letters: it demonstrates that evolocumab is effective and tolerable in the statin-intolerant population that PAs are most likely to cover.

For Maine prescribers filing a PA on the basis of statin intolerance, documentation should include the names and doses of at least two statins tried, the nature of the adverse effect for each, confirmation that symptoms resolved upon discontinuation, and evidence that ezetimibe monotherapy was either tried or contraindicated. A letter from a cardiologist or clinical pharmacist reviewing the lipid history strengthens the submission considerably.

Comparing Evolocumab to Alirocumab in Maine

Evolocumab (Repatha) and alirocumab (Praluent) are both approved PCSK9 inhibitors with comparable LDL-C reduction profiles. The choice between them in Maine is frequently driven by formulary tier rather than clinical differentiation. Some Maine commercial plans place alirocumab on a lower tier than evolocumab in a given plan year, making alirocumab the lower out-of-pocket option even though the clinical efficacy is similar [20].

The ODYSSEY OUTCOMES trial (N=18,924) demonstrated alirocumab reduced major adverse cardiovascular events by 15% relative to placebo in post-ACS patients, a magnitude comparable to FOURIER's cardiovascular outcome results [21]. Patients and prescribers in Maine should check both drugs' tier placement on the specific formulary before defaulting to one PCSK9 inhibitor. If a plan's PA department confirms that evolocumab and alirocumab carry identical criteria, switching to the lower-tier agent requires only a new PA filed for alirocumab, which many cardiology practices complete within one to two business days.

Finding Evolocumab in Maine: Pharmacies and Dispensing Logistics

Major retail pharmacy chains with Maine locations that can dispense brand Repatha include CVS, Walgreens, Hannaford Pharmacy, and Rite Aid (where locations remain open following corporate restructuring). Specialty pharmacy networks including Accredo, Optum Specialty Pharmacy, and Walgreens Specialty are the primary dispensing channels for commercially insured patients, as most PCSK9 prescriptions route through specialty pharmacy benefit management under commercial plans [22].

Repatha requires refrigeration at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius). The autoinjector can be stored at room temperature (up to 77 degrees Fahrenheit / 25 degrees Celsius) for up to 30 days if kept in the original carton away from light. Maine's climate is relevant here: summer temperatures in southern Maine can exceed 90 degrees Fahrenheit, and patients who receive a 90-day supply via mail-order should confirm packaging includes gel-pack refrigeration sufficient for transit time.

The FDA's prescribing information for evolocumab specifies that patients who miss a dose should administer it within 7 days of the scheduled date for the biweekly regimen, or restart on the original schedule if more than 7 days have passed [23]. For the monthly 420 mg regimen, a missed dose should be administered within 7 days of the missed date.